Dr. Stephen Smith
Claim this profileFred Hutch/University of Washington Cancer Consortium
Studies Lymphoma
Studies Follicular Lymphoma
9 reported clinical trials
27 drugs studied
Area of expertise
1Lymphoma
CD19 positive
Stage II
Stage I
2Follicular Lymphoma
CD19 positive
CCND1 positive
t(11;14) positive
Affiliated Hospitals
Clinical Trials Stephen Smith is currently running
Immunotherapy + Chemotherapy
for Lymphoma
This phase I/II trial tests the safety of tafasitamab, retifanlimab, and rituximab (TRR) as a prephase treatment and in combination with standard therapy consisting off cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or polatuzumab vedotin, cyclophosphamide, doxorubicin, and prednisone (PolaCHP) in patients with untreated diffuse large B-cell lymphoma. Tafasitamab, retifanlimab, and rituximab are monoclonal antibodies. Tafasitamab binds to a protein called CD19, which is found on B-cells (a type of white blood cell) and some types of cancer cells. Rituximab binds to a protein called CD20, which is also found on B-cells and some cancer cells. These monoclonal antibodies may help the immune system kill cancer cells. Immunotherapy with other monoclonal antibodies, such as retifanlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as CHOP and PolaCHP, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving TRR in combination with CHOP or PolaCHP may kill more cancer cells.
Recruiting1 award Phase 1 & 2
Loncastuximab Tesirine
for B-Cell Lymphoma
This trial is testing a new treatment called loncastuximab tesirine for patients whose B-cell cancers have returned or don't respond to other treatments. The treatment uses a special protein to find cancer cells and deliver a chemotherapy drug directly to them. Patients receive this treatment periodically and are monitored for several years after treatment. Loncastuximab tesirine has been previously tested in an earlier study for similar conditions.
Recruiting2 awards Phase 2
More about Stephen Smith
Clinical Trial Related1 year of experience running clinical trials · Led 9 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Stephen Smith has experience with
- Rituximab
- Cyclophosphamide
- Rituximab And Hyaluronidase Human
- Doxorubicin
- Acalabrutinib
- Doxorubicin Hydrochloride
Breakdown of trials Stephen Smith has run
Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
Non-Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Stephen Smith specialize in?
Stephen Smith focuses on Lymphoma and Follicular Lymphoma. In particular, much of their work with Lymphoma has involved CD19 positive patients, or patients who are Stage II.
Is Stephen Smith currently recruiting for clinical trials?
Yes, Stephen Smith is currently recruiting for 4 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that Stephen Smith has studied deeply?
Yes, Stephen Smith has studied treatments such as Rituximab, Cyclophosphamide, Rituximab and Hyaluronidase Human.
What is the best way to schedule an appointment with Stephen Smith?
Apply for one of the trials that Stephen Smith is conducting.
What is the office address of Stephen Smith?
The office of Stephen Smith is located at: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington 98109 United States. This is the address for their practice at the Fred Hutch/University of Washington Cancer Consortium.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.